Anzeige
Mehr »
Sonntag, 10.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWUU | ISIN: US00534A1025 | Ticker-Symbol:
NASDAQ
08.08.25 | 21:59
0,798 US-Dollar
+5,93 % +0,045
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
INVIVYD INC Chart 1 Jahr
5-Tage-Chart
INVIVYD INC 5-Tage-Chart

Aktuelle News zur INVIVYD Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.07.Long-COVID-Forschung: Invivyd holt renommierte Yale-Immunbiologin an Bord2
INVIVYD Aktie jetzt für 0€ handeln
23.07.Yale immunobiologist Iwasaki joins Invivyd's Long COVID research group1
23.07.Invivyd: Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome1
21.07.Invivyd: National Comprehensive Cancer Network (NCCN) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population1
02.07.Invivyd forms research group to study monoclonal antibodies for Long COVID2
02.07.Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome2
27.06.H.C. Wainwright behält Kaufempfehlung für Invivyd-Aktie nach positiven Daten bei2
27.06.H.C. Wainwright maintains buy rating on Invivyd stock after positive data1
26.06.Invivyd claims Pemgarda mAB follow-up could hold its own against COVID vaccines1
26.06.Invivyd, Inc. - 8-K, Current Report2
26.06.Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection106Attractive safety profile demonstrated across all dosing cohorts and routes of administration (IV, SC, and IM); all reported adverse events (AEs) deemed unrelated or classified as mild to moderate...
► Artikel lesen
29.05.H.C. Wainwright senkt Kursziel für Invivyd-Aktie auf 5 US-Dollar, behält Kaufempfehlung bei-
29.05.Invivyd stock target cut to $5 by H.C. Wainwright, retains Buy rating2
27.05.Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, ...230CANOPY assessed pemivibart safety and tolerability, antiviral immunobridging, and exploratory efficacy against COVID-19, and is the only clinical trial of an authorized or approved COVID-19 monoclonal...
► Artikel lesen
23.05.Invivyd's antibody gains spot in cancer guidelines for COVID-19 PrEP2
23.05.Invivyd Announces Inclusion of PEMGARDA (pemivibart) in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas172WALTHAM, Mass., May 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National...
► Artikel lesen
21.05.Invivyd Says Pemivibart Confers 84% Reduction In COVID-19 Risk, To Engage FDA With Expedited Pathway1
21.05.Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19168FDA acknowledges that the benefit of repeat doses of COVID-19 vaccine boosters for Americans is uncertain; the updated regulatory framework for COVID-19 vaccines articulated by the Agency generally...
► Artikel lesen
20.05.Invivyd, Inc. - 8-K, Current Report4
15.05.Invivyd Q1 2025 slides: Revenue grows amid regulatory hurdles and cash concerns3
Weiter >>
68 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1